Institutions / Tri Locum Partners LP
Tri Locum Partners LP
CIK 1826434 · Institution · as of Dec 31, 2025
Portfolio value
$770.12M
Positions
15
As of
Dec 31, 2025
Top holdings
Dec 31, 2025
| Company | Value | % of portfolio |
|---|---|---|
| Johnson & Johnson | $124.82M | 16.2% |
| Danaher Corp /De | $79.41M | 10.3% |
| ELI LILLY & Co | $68.01M | 8.8% |
| United Therapeutics Corp | $58.92M | 7.7% |
| Ascendis Pharma A/S | $56.51M | 7.3% |
| Madrigal Pharmaceuticals, Inc. | $50.09M | 6.5% |
| Boston Scientific Corp | $49.63M | 6.4% |
| Teva Pharmaceutical Industries LtdTEVA | $44.81M | 5.8% |
| Ionis Pharmaceuticals Inc | $44.08M | 5.7% |
| Vera Therapeutics, Inc. | $40.80M | 5.3% |
| Axsome Therapeutics, Inc. | $36.83M | 4.8% |
| Argenx SE | $31.66M | 4.1% |
| Nuvalent, Inc. | $30.92M | 4.0% |
| Dexcom Inc | $27.98M | 3.6% |
| Dianthus Therapeutics, Inc. | $25.65M | 3.3% |
Activity
Dec 31, 2025
InsidersInstitutions
This fund's 13F position changes — what it's buying and selling.No quarter-over-quarter changes yet — position changes appear once we've ingested two consecutive 13F filings for this manager. We currently hold 1 quarter of holdings.